Hema Tallman on Incredible Opportunity to Participate in the PPTA 2025 Meetings
Hema Tallman, SVP- Global Head of BioLife Plasma Services at Takeda, shared on LinkedIn:
”I recently had the incredible opportunity to participate in the Plasma Protein Therapeutics Association (PPTA) meetings, both at the Plasma Protein Forum and the Business Forum.
Engaging with fellow industry members during these discussions was enlightening and enriching.
Speaking on a panel at the Business Forum—a meeting dedicated solely to plasma industry members—was a particular highlight.
We delved into crucial topics like ethical decision-making, the importance of industry collaboration, and the need for a broader industry representation in PPTA, which are crucial for driving progress in our field.
I’m proud to represent Takeda and BioLife Plasma Services and contribute to conversations on how we can collectively shape the future, ensure ethical practices, and meet patient needs.
Advocacy, transparency, and education remain paramount as we work towards improving both understanding and perception of the plasma industry across the globe.
Grateful for the opportunity to engage and learn, I look forward to continuing these important efforts alongside my esteemed colleagues to work collectively and collaboratively to meet patient needs!”
Stay updated with Hemostasis Today.
-
Jan 20, 2026, 16:34Fernanda Orsi Explores Brazilian Registry of Thrombotic Thrombocytopenic Purpura
-
Jan 20, 2026, 16:15Tareq Abadl on Bacterial Contamination of Platelets
-
Jan 20, 2026, 15:53Ruzanna Papyan on Neuroblastoma Risk Stratification in Real-World Settings
-
Jan 20, 2026, 13:35Omar Shaltout On Stories Behind Memorable Cases
-
Jan 20, 2026, 13:25Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
-
Jan 20, 2026, 13:15Benjamin YQ Tan on Precision Lipid Management After Stroke
-
Jan 20, 2026, 13:08Antonio Paul on Blame Game in Transplantation: HLA vs Microbes
-
Jan 20, 2026, 12:33Dario Tuccinardi on Obesity as Cardiovascular Treatment Target
-
Jan 20, 2026, 12:18Ed Shovelin on CRP-A Utilization in Diverse Research Areas